Zynerba Pharmaceuticals: Analysts See More Upside after the RallyZynerba PharmaceuticalsSo far, Zynerba Pharmaceuticals (ZYNE) has seen an upwards price action of 265% in 2019. Analysts see more upside in the stock. The mean consensus target price